Cancer clinical trials in the region Île-de-France
787 currently recruiting clinical trials
Looking for clinical trials?
Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:
- Create your account
- Copy-paste your latest medical report
- Our AI-based assistant does the rest for you
Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:
Phase 1 / Phase 2
Lung cancer
#NCT06892548
#2024-520238-31-00
Partie 2 - Cohortes 3 et 5
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Squamous NSCLC
Non-squamous NSCLC
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Excluded genetic anomalies
ALK
BRAF
EGFR
HER2
KRAS G12C
MET
NTRK-1/2/3
RET
ROS-1
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
4 recruiting sites
BioNTech SE
Phase 1 / Phase 2
Lung cancer
#NCT06892548
#2024-520238-31-00
Partie 2 - Cohorte 1 et 4
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Squamous NSCLC
Non-squamous NSCLC
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
ALK
BRAF
EGFR
HER2
KRAS G12C
MET
NTRK-1/2/3
RET
ROS-1
Excluded previous treatments at localized stage
Antibody Drug Conjugates (ADC)
Excluded previous treatments at advanced or metastatic stage
Antibody Drug Conjugates (ADC)
4 recruiting sites
BioNTech SE
Phase 1 / Phase 2
Lung cancer
#NCT06892548
#2024-520238-31-00
Partie 2 - Cohorte 7
Required histologic types
SCLC (Small Cell Lung Cancer)
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
4 recruiting sites
BioNTech SE
Phase 1 / Phase 2
Lung cancer
#NCT06892548
#2024-520238-31-00
Partie 2 - Cohorte 2
Required histologic types
SCLC (Small Cell Lung Cancer)
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
4 recruiting sites
BioNTech SE
Phase 1 / Phase 2
Lung cancer
#NCT06772623
#2024-514465-18-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Non-squamous NSCLC
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
ALK
BRAF
EGFR
HER2
HRAS
KRAS G12C
KRAS non G12C
MET
NTRK-1/2/3
RET
ROS-1
7 recruiting sites
Abbvie
Phase 1 / Phase 2
Acute leukemia
#NCT04988555
#2022-502741-10-00
Phase 1, bras A, B, E et F
Required histologic types
Acute lymphoblastic leukemia (ALL)
Acute myeloid leukemia (AML)
Other acute leukemia
Required central nervous system lesions
None
Treated / Controled
Required renal function statuses
> 60 ml/min
50-60 ml/min
Required genetic anomalies
KMT2A
MLL fusions
NPM1
Required number of previous lines of therapy
1
2
3 or more
Excluded previous treatments
Systemic Treatment-Naive
8 recruiting sites
Sumitomo Pharma America, Inc.
Phase 1 / Phase 2
Lymphoma
#NCT06564038
#2024-515034-33-00
Cohorte 2A et 2C
Required histologic types
B cell lymphoma
Required histologic sub types
Mantel cell lymphoma
Required disease stage
Early (stage I and II)
Disseminated (stage III and IV)
Required number of previous lines of therapy
2
3 or more
Required previous treatments
Targeted therapy
Excluded previous treatments
Systemic Treatment-Naive
5 recruiting sites
AstraZeneca
Phase 1 / Phase 2
Lymphoma
#NCT06564038
#2024-515034-33-00
Cohortes 3A et 3B Lymphome à grandes cellules B
Required histologic types
B cell lymphoma
Required histologic sub types
Large B cell lymphoma
Required number of previous lines of therapy
None
4 recruiting sites
AstraZeneca
Phase 1 / Phase 2
Lymphoma
#NCT06564038
#2024-515034-33-00
Cohorte 3A Lymphomes B non hodgkinien R/R
Required histologic types
B cell lymphoma
Required histologic sub types
Mantel cell lymphoma
Follicular lymphoma
Marginal zone lymphoma
MALT lymphoma
Lymphocytic lymphoma
Indolent transformed lymphoma
Required number of previous lines of therapy
1
2
3 or more
Excluded previous treatments
Systemic Treatment-Naive
4 recruiting sites
AstraZeneca
Phase 1 / Phase 2
Lymphoma
CLL & Richter's syndrome
#NCT06564038
#2024-515034-33-00
Cohorte 1A et 1C
Required histologic types
B cell lymphoma
CLL (Chronic Lymphocytic Leukemia)
Required histologic sub types
Lymphocytic lymphoma
Required number of previous lines of therapy
2
3 or more
Excluded previous treatments
Systemic Treatment-Naive
4 recruiting sites
AstraZeneca